Application of Real-time Quantitative PCR in Detecting Atypical BCR/ABL mRNA Transcripts in Chronic Myelocytic Leukemia.
- VernacularTitle:BCR/ABL融合基因少见型实时荧光PCR定量检测在慢性髓系白血病中的应用
- Author:
Yuan ZOU
1
;
Cui DU
1
;
Hong-Mei CHEN
2
;
Fu-Xiao GUO
1
;
Jian-Bing CHENG
1
;
Yuan-Yan TANG
1
;
Wei WU
1
;
Cheng-Qing XIA
1
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2017;25(4):1016-1021
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect atypical BCR/ABL mRNA transcript by real-time quantitative PCR in CML patients without e13a2/e14a2,e19a2 or e1a2 transcripts, and investigate its value of clinical application.
METHODSTwelve cases of CML with positive for t(9;22) translocation, but negative for common major and minor breakpoint cluster regions comfirmed by chromosome karyotyping or FISH analysis, were collected from July 2012 to December 2015. These 12 cases were then detected for b2a3(e13a3), b3a3(e14a3), e6a2, e8a2 and e1a3 fusion variants by real-time quantitative PCR.
RESULTSAmong 12 cases 4 variant transcripts were detected, including e1a3 in 1 case (8.33%), e8a2 in 2 cases (16.67%), b2a3 in 5 cases (41.67%) and b3a3 in 4 cases (33.33%), with total positivity of 100%, moreover b2a3 and b3a3 were predominant.
CONCLUSIONThe detecting atypical BCR/ABL mRNA transcripts by real-time quantitative PCR is suitable for the diagnosis of CML negative for P210, P190 and P230 by standard real-time PCR test, and this detection is still the standard and economic method for monitoring minimal residual disease in CML patients with variants of BCR/ABL fusion gene.
